Aimmune Therapeutics Target of Unusually Large Options Trading (AIMT)

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) saw unusually large options trading activity on Tuesday. Stock investors purchased 723 put options on the stock. This represents an increase of approximately 877% compared to the average daily volume of 74 put options.

Aimmune Therapeutics (NASDAQ:AIMT) opened at $38.83 on Friday. Aimmune Therapeutics has a fifty-two week low of $15.97 and a fifty-two week high of $40.65. The company has a market cap of $1,940.00 and a price-to-earnings ratio of -16.59.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. equities analysts anticipate that Aimmune Therapeutics will post -2.51 EPS for the current year.

Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Credit Suisse Group raised their price objective on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. Wedbush reaffirmed an “outperform” rating and issued a $70.00 price objective (up from $42.00) on shares of Aimmune Therapeutics in a report on Monday, October 23rd. BidaskClub downgraded shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, December 9th. Finally, Robert W. Baird assumed coverage on shares of Aimmune Therapeutics in a report on Wednesday, December 20th. They issued an “outperform” rating and a $64.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $55.43.

In other news, insider Daniel C. Md Adelman sold 9,933 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $40.00, for a total transaction of $397,320.00. Following the completion of the sale, the insider now owns 26,784 shares in the company, valued at approximately $1,071,360. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Daniel C. Md Adelman sold 3,283 shares of the firm’s stock in a transaction that occurred on Thursday, December 27th. The stock was sold at an average price of $40.00, for a total transaction of $131,320.00. Following the completion of the transaction, the insider now directly owns 3,283 shares of the company’s stock, valued at $131,320. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 173,509 shares of company stock valued at $6,429,588. 24.56% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in AIMT. Citadel Advisors LLC boosted its holdings in Aimmune Therapeutics by 3,092.5% in the 3rd quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock valued at $13,873,000 after purchasing an additional 542,111 shares during the period. Vanguard Group Inc. boosted its holdings in Aimmune Therapeutics by 12.6% in the 2nd quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock valued at $50,923,000 after purchasing an additional 276,978 shares during the period. State Street Corp boosted its holdings in Aimmune Therapeutics by 26.6% in the 2nd quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock valued at $22,351,000 after purchasing an additional 228,429 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Aimmune Therapeutics by 139.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock valued at $4,675,000 after purchasing an additional 132,603 shares during the period. Finally, Palo Alto Investors LLC boosted its holdings in Aimmune Therapeutics by 9.9% in the 2nd quarter. Palo Alto Investors LLC now owns 1,289,719 shares of the biotechnology company’s stock valued at $26,517,000 after purchasing an additional 116,221 shares during the period. 73.34% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Aimmune Therapeutics Target of Unusually Large Options Trading (AIMT)” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/19/aimmune-therapeutics-target-of-unusually-large-options-trading-aimt.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply